TTIPF (Thiogenesis Therapeutics) Common Stock: $14.52 Mil (As of Mar. 2026)


TTIPF Thiogenesis Therapeutics Corp TTIPF
12 GF Score
Price $0.42
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics Common Stock?

Thiogenesis Therapeutics TTIPF -6.67% 12 Common Stock is $14.52 Mil as of Mar. 2026. GuruFocus rates TTIPF with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Thiogenesis Therapeutics's quarterly common stock increased from Sep. 2025 ($14.39 Mil) to Dec. 2025 ($14.44 Mil) and increased from Dec. 2025 ($14.44 Mil) to Mar. 2026 ($14.52 Mil).

Thiogenesis Therapeutics's annual common stock increased from Dec. 2023 ($11.19 Mil) to Dec. 2024 ($11.33 Mil) and increased from Dec. 2024 ($11.33 Mil) to Dec. 2025 ($14.44 Mil).

Thiogenesis Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Thiogenesis Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics Common Stock Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 0.21 0.24 11.19 11.33 14.44

Thiogenesis Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.29 11.86 14.39 14.44 14.52
TTIPF
12GF Score
Thiogenesis Therapeutics Corp TTIPF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thiogenesis Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $14.52 Mil mean?
Thiogenesis Therapeutics (TTIPF) has a Common Stock of $14.52 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Thiogenesis Therapeutics and its competitors.
Is Thiogenesis Therapeutics' Common Stock too high?
Thiogenesis Therapeutics' current Common Stock is $14.52 Mil. Overall, Thiogenesis Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' Common Stock compare to VRTX and REGN?
Thiogenesis Therapeutics' Common Stock of $14.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Thiogenesis Therapeutics and its competitors. Thiogenesis Therapeutics's current Common Stock is $14.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (TTIPF) has a current Common Stock of $14.52 Mil. The current Common Stock is $14.52 Mil. Thiogenesis Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Thiogenesis Therapeutics (TTIPF), the current Common Stock is $14.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thiogenesis Therapeutics Business Description

Other Exchanges Q8M:GermanyTTI:Canada
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
12GF Score

Get the complete analysis for TTIPF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price